Increased Circulating Insulin-like Growth Factor-1 in Late-onset Alzheimer's Disease
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Insulin-like growth factor (IGF)-1 has been implicated in the pathogenesis of Alzheimer's disease (AD). METHODS: We compared the level of circulating total and bioavailable IGF-1, by simultaneous measurements of IGF-1 and IGF binding protein (IGFBP)-3, between 87 patients diagnosed with AD and 126 age and sex matched control subjects without cognitive impairment. Blood samples were collected and IGF-1 and IGFBP-3 measured by ELISA. Subjects were also genotyped for apolipoprotein E. RESULTS: Total circulating IGF-1 levels were significantly raised in the AD group as compared to the control group (p=0.022). There was no significant difference in the circulating level of IGFBP-3 between the two groups. When the IGF-1 levels were ratioed against IGFBP-3 levels as an indicator of unbound, bioavailable circulating IGF-1, there was a significant increase in the molar IGF-1:IGFBP-3 ratio in the AD subjects (0.181 +/- 0.006) as compared to the controls (0.156 +/- 0.004) (p< 0.001). Logistic regression analysis revealed that an increase in the IGF-1:IGFBP-3 molar ratio increased the risk of AD significantly. CONCLUSION: The results of increased total and free circulating IGF-1 support the hypothesis that in its early stages late-onset AD reflects a state of resistance to IGF-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114 · cited 3×
“…age, gender, alcohol intake (past or present), education (years of schooling or university attendance), prevalence of cerebrovascular or cardiovascular disease,fast-E ing blood sugar, fasting plasma insulin or insulin resistance as defined by the homeostasis model assessment (HOMA) [31] (Table 1).”
InfluentialCirculating Insulin-Like Growth Factor I Mediates Effects of Exercise on the Brain
Carro, E., Nuñez, A., Busiguina, S., & Torres-Aleman, I. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-08-02926.2000 · Cited by 762 · cited 1×
“Although IGF-1, its receptor and binding proteins are present and locally produced in the brain [27], IGF1 is actively transported across the blood-brain barrier, and therefore changes in circulating IGF-1 can lead to changes in IGF-1 input to the brain [4].”
Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723
Craft, S., Peskind, E., Schwartz, M. W., Schellenberg, G. D., Raskind, M., & Porte, D. (1998) · Neurology · doi:10.1212/wnl.50.1.164 · Cited by 560 · cited 1×
“There was a significantly greater prevalence of diabetes mellitus in the AD group ( p = 0 .”
Schofield, P. W., Logroscino, G., Andrews, H. F., Albert, S., & Stern, Y. (1997) · Neurology · doi:10.1212/wnl.49.1.30 · Cited by 203 · cited 1×
“Secondary findings included significant associations between stature, head circumference, weight, BMI, ApoE4 allele and AD consistent with previous studies [1,2,21,26].”
Cited by
The Role of Liver-Derived Insulin-Like Growth Factor-I
Ohlsson, C., Mohan, S., Sjögren, K., Tivesten, A., Isgaard, J., Isaksson, O., Jansson, J.-O., & Svensson, J. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0010 · Cited by 453
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P.-O., Bezard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 309
Aberrant insulin signaling in Alzheimer's disease: current knowledge
Bedse, G., Di Domenico, F., Serviddio, G., & Cassano, T. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00204 · Cited by 292
Freude, S., Hettich, M. M., Schumann, C., Stöhr, O., Koch, L., Köhler, C., Udelhoven, M., Leeser, U., Müller, M., Kubota, N., et al. (2009) · The FASEB Journal · doi:10.1096/fj.09-132043 · Cited by 218
“Moreover, brain IGF-1 mRNA levels are diminished in late AD, whereas IGF-1 serum levels are increased in early stages of disease, suggesting that IGF-1 resistance plays a role in the pathogenesis of AD (14, 41).”
BackgroundLandel, V., Baranger, K., Virard, I., Loriod, B., Khrestchatisky, M., Rivera, S., Benech, P., & Féron, F. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-33 · Cited by 176
“Insulin and IGF1 signaling is disturbed in AD brain and in 5XFAD hippocampus [120,148,149].”
Keeney, J. T.-R., Ibrahimi, S., & Zhao, L. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150348 · Cited by 102
Xu, J., Begley, P., Church, S. J., Patassini, S., McHarg, S., Kureishy, N., Hollywood, K. A., Waldvogel, H. J., Liu, H., Zhang, S., et al. (2016) · Scientific Reports · doi:10.1038/srep27524 · Cited by 85
Self-citationCho, Z., Oh, S., Kim, J., Park, S., Kwon, D., Jeong, H., Kim, Y., Chi, J., Park, C., Huston, J., et al. (2011) · Movement Disorders · doi:10.1002/mds.23465 · Cited by 87
Metadata
- Authors
- Vardy, E. R. L. C., Rice, P. J., Bowie, P. C. W., Holmes, J. D., Grant, P. J., & Hooper, N. M.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2007-12-25
- Volume
- 12
- Issue
- 4
- Pages
- 285-290
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1515568852
- Cited by
- 91
- References
- 5
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.